Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The breast microbiome
- Microbiome and breast cancer risk
- Collating the data available
- Impact of breast colonization with ETBF
- Does presence of ETBF in the gut impact breast carcinogenesis?
- Changes to the mammary glands
- How does BFT impact breast epithelial cells?
- Molecular analysis with Raman spectroscopy
- How does BFT alter cell physiology?
- Microbiota of 11 solid tumors
- F. nucleatum in breast tissue
- Increased accumulation resulted in increased lung metastasis
- ETBF enhanced breast cancer aggressiveness in syngeneic mice model
- Mice model results
- Tumor-resident intracellular microbiota promotes metastatic colonization
- Beyond association
- Gut microbiota in cancer progression
- The future of cancer microbiome
- References
- Further reading
Topics Covered
- The breast microbiome
- Cancer microbiome
- Microbiome and carcinogenesis
- Enterotoxigenic B. fragilis
- F. nucelatum
- Gut microbiota and cancer progression
Talk Citation
Parida, S. (2023, May 31). Alterations in the human microbiome and its implications on cancer risk: microbiome and carcinogenesis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/RGZQ8093.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Sheetal Parida has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Alterations in the human microbiome and its implications on cancer risk: microbiome and carcinogenesis
Published on May 31, 2023
25 min
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:05
This is a timeline of the
breast microbiome research,
and from the very beginning
it was basically focused
on the microbial communities
and human breast milk,
since that was the first source
of immunoglobulins to the infant
that stimulated
the immune system
of the infant basically,
and it was found
that it did have
some beneficial microbes
in it and around 2014,
it was found that
microbial composition of
the breast milk was very
similar to nipple aspirate fluid
of women even after weening.
Initially, it was thought
that it would be because
there is an orifice and
opening to the environment,
it must be a
environmental exchange
rather than an intrinsic
component of the milk,
but with further studies
it was found that
it's not really an
environmental exchange,
but it depended on
the maternal diet
and it was actually
a component of the
breast milk as well
as nipple aspirate fluids.
1:01
Coming to microbiome and its
relation to breast cancer
risk,impaired microbiota in
the gut as well as
the local breast
microbiota can lead to
downstream signaling
pathways which
can lead to carcinogenesis.
In 2014, Urbaniak and group,
they screened breast tissue from
multiple sites around
the breast of women
18-90 years old in two different
cohorts of Canadian
and Irish woman,
and both cohorts
harbored rich microbial
communities independent
of the lactation status,
and in a successive study,
they compared the microbiota of
the normal breast to
the breast tumors,
and this was really
the beginning of
breast cancer
microbiota association.
In 2016, Lee et al
characterized the nipple
aspirate fluid of
healthy woman and
breast cancer survivors
and they did find
significant differences.
Another study in 2016
had characterized
the microbiota of benign and
malignant breast tumors,
and within a few years
multiple studies were
published that descriptively
characterized the breast cancer
associated breast microbiome and
gut microbiome and few
identified sub-type specific
signatures as well.
So breast cancer has
different subtypes.
It's really not a
single disease,
it's a category of diseases.
We have hormone receptor
positive breast cancers,
ER/PR triple negative
breast cancers
as well as HER2
enriched breast cancer.
And studies have found
that different subtypes of
breast cancer is associated
with different
microbial signatures,
and hormone regulation,
obesity and
microbial metabolites were
postulated to be responsible for
microbiome-breast
cancer association
and microbiome induced
immunometabolism and
mechanistic studies
gained importance post 2018.
Hide